| Recent trends in epidemiology of brain metastases: an overview E Tabouret, O Chinot, P Metellus, A Tallet, P Viens, A Goncalves Anticancer research 32 (11), 4655-4662, 2012 | 413 | 2012 |
| CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas R Appay, C Dehais, CA Maurage, A Alentorn, C Carpentier, C Colin, ... Neuro-oncology 21 (12), 1519-1528, 2019 | 234 | 2019 |
| SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution RJ Argüello, AJ Combes, R Char, JP Gigan, AI Baaziz, E Bousiquot, ... Cell metabolism 32 (6), 1063-1075. e7, 2020 | 228 | 2020 |
| Management and outcome of primary CNS lymphoma in the modern era: an LOC network study C Houillier, C Soussain, H Ghesquières, P Soubeyran, O Chinot, ... Neurology 94 (10), e1027-e1039, 2020 | 150 | 2020 |
| Complications related to the endoscopic endonasal transsphenoidal approach for nonfunctioning pituitary macroadenomas in 300 consecutive patients E Magro, T Graillon, J Lassave, F Castinetti, S Boissonneau, E Tabouret, ... World neurosurgery 89, 442-453, 2016 | 130 | 2016 |
| Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort E Tabouret, AT Nguyen, C Dehais, C Carpentier, F Ducray, A Idbaih, ... Acta neuropathologica 132, 625-634, 2016 | 114 | 2016 |
| Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial T Graillon, M Sanson, C Campello, A Idbaih, M Peyre, H Peyrière, ... Clinical Cancer Research 26 (3), 552-557, 2020 | 111 | 2020 |
| FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan C Colavolpe, O Chinot, P Metellus, J Mancini, M Barrie, ... Neuro-oncology 14 (5), 649-657, 2012 | 83 | 2012 |
| Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression E Tabouret, C Cauvin, S Fuentes, B Esterni, T Adetchessi, N Salem, ... The spine journal 15 (5), 944-950, 2015 | 80 | 2015 |
| Challenges in glioblastoma research: focus on the tumor microenvironment A Bikfalvi, CA da Costa, T Avril, JV Barnier, L Bauchet, L Brisson, ... Trends in cancer 9 (1), 9-27, 2023 | 79 | 2023 |
| Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB … D Figarella-Branger, E Lechapt-Zalcman, E Tabouret, S Jünger, ... Neuro-oncology 18 (7), 919-927, 2016 | 73 | 2016 |
| Clinical management of diffuse low-grade gliomas G Lombardi, V Barresi, A Castellano, E Tabouret, F Pasqualetti, ... Cancers 12 (10), 3008, 2020 | 59 | 2020 |
| Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma E Tabouret, F Boudouresque, M Barrie, M Matta, C Boucard, A Loundou, ... Neuro-oncology 16 (3), 392-399, 2014 | 59 | 2014 |
| MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma E Tabouret, F Boudouresque, P Farina, M Barrié, C Bequet, M Sanson, ... Neuro-oncology 17 (8), 1174-1176, 2015 | 58 | 2015 |
| Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature G Lombardi, AL Di Stefano, P Farina, V Zagonel, E Tabouret Cancer treatment reviews 40 (8), 951-959, 2014 | 57 | 2014 |
| Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults T Picart, M Barritault, D Poncet, LP Berner, C Izquierdo, E Tabouret, ... Neuro-Oncology Advances 3 (1), vdab061, 2021 | 54 | 2021 |
| Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway E Tabouret, A Tchoghandjian, E Denicolai, C Delfino, P Metellus, ... Oncotarget 6 (13), 11664, 2015 | 53 | 2015 |
| Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 A Tchoghandjian, A Soubéran, E Tabouret, C Colin, E Denicolaï, ... Cell death & disease 7 (8), e2325-e2325, 2016 | 52 | 2016 |
| Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial E Tabouret, C Houillier, N Martin-Duverneuil, M Blonski, C Soussain, ... Neuro-oncology 19 (3), 422-429, 2017 | 50 | 2017 |
| Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads K Baumstarck, O Chinot, E Tabouret, P Farina, M Barrié, C Campello, ... Health and Quality of Life Outcomes 16, 1-10, 2018 | 49 | 2018 |
